PFIZER PRESENTS OVERALL SURVIVAL DATA FOR SUTENT™ VERSUS INTERFERON-ALFA

Chicago, 31 May 2008- Results from a landmark study have shown that sunitinib (SUTENT™) has demonstrated overall survival greater than two years in patients with metastatic renal cell carcinoma (mRCC), also known as advanced kidney cancer.  This is the first time overall survival data representing more than two years has been achieved in the first line setting of mRCC, which is clinically meaningful and reflective of major advances in the treatment of kidney cancer. 
More info >>

EuroBiopartnering 2008

7-9 October 2008, Paris, France

EuroBiOpartnering 2008 gives you the unique opportunity to meet the relevant decision makers and opinion leaders from the international biotech community and offers you 3 days of partnering opportunities including one-to-one meetings, company presentations and further networking activities…
More info >>